(9CI)-吡啶并[2,3-b]吡嗪-3-胺 | 155535-24-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶吡嗪类
• 中文名称: (9CI)-吡啶并[2,3-b]吡嗪-3-胺
• 英文名称: 3-amino-pyridinopyrazine
• 英文别名: 3-amino-pyridopyrazine；Pyrido[2,3-b]pyrazin-3-amine
• CAS: 155535-24-3
• 化学式: C₇H₆N₄
• 分子量: 146.151
• InChiKey: HZIJFLKTAFJCLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (9CI)-吡啶并[2,3-b]吡嗪-3-胺 在 水 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 (9-isopropylimidazo[1,2-a]pyrido[3,2-e]pyrazine-8-yl)(piperazin-1-yl)methanone
  参考文献：
  名称：

  一类toll样受体调节剂、其药物组合物、制备方 法与用途

  摘要：

  本发明属于药物化学领域，具体涉及一类具有toll样受体调节作用的化合物、其制备方法及用途。本发明提供如下式X所示的化合物。式X化合物可用作toll样受体调节剂，其活性较高。此外，本发明化合物具有高效低毒、抗耐药性等特点，具有临床应用价值。并且，本发明化合物合成步骤简单，因此具备较大的经济利用价值。

  公开号：

  CN108794485B

文献信息

• [EN] PYRIDO[2,3-B]PYRAZINE-8-SUBSTITUTED COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS PYRIDO[2,3-B]PYRAZINE SUBSTITUÉS EN POSITION 8 ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009077766A1

  公开（公告）日：2009-06-25

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明一般涉及用于治疗增殖性疾病、癌症等的治疗化合物领域，更具体地涉及到本文所述的某些吡啶并[2,3-b]吡嗪-8-取代化合物，该化合物在某些情况下抑制RAF（例如BRAF）活性。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体内外抑制RAF（例如BRAF）活性、抑制受体酪氨酸激酶（RTK）活性、抑制细胞增殖，并用于治疗通过抑制RAF、RTK等而得到改善的疾病和疾患，如癌症（例如结直肠癌、黑色素瘤）等。
• NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF
  申请人：Gerlach Matthias

  公开号：US20090275534A1

  公开（公告）日：2009-11-05

  The invention relates to pyrido[2,3-b]pyrazine compounds of general formulae (Ia) and (Ib), to their preparation and use, for example, for the treatment of malignant disorders and other disorders based on pathological cell proliferations.

  本发明涉及一般式(Ia)和(Ib)的吡啶并[2,3-b]吡嗪类化合物，以及它们的制备和用途，例如用于治疗恶性疾病和其他基于病理细胞增殖的疾病。
• Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use
  申请人：Springer Caroline Joy

  公开号：US20120238568A1

  公开（公告）日：2012-09-20

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明涉及治疗增生性疾病、癌症等的治疗化合物领域，更具体地涉及某些在此处描述的吡啶并[2,3-b]吡嗪-8-取代化合物，它们在诸多方面抑制RAF（例如B-RAF）活性。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制RAF（例如BRAF）活性，抑制受体酪氨酸激酶（RTK）活性，抑制细胞增殖，并用于治疗由于抑制RAF、RTK等而改善的疾病和疾病，如增生性疾病（例如结直肠癌、黑色素瘤）等。
• PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE
  申请人：INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)

  公开号：US20150182526A1

  公开（公告）日：2015-07-02

  The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc.

  本发明涉及治疗增生性疾病、癌症等的治疗化合物领域，更具体地涉及某些在此处描述的吡啶并[2,3-b]吡嗪-8-取代化合物，它们在其他方面抑制RAF（例如B-RAF）活性。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制RAF（例如BRAF）活性，抑制受体酪氨酸激酶（RTK）活性，抑制细胞增殖，并治疗由于抑制RAF，RTK等而改善的疾病和疾患，如癌症（例如结直肠癌，黑色素瘤）等。
• COMPOSITION AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME
  申请人：Samsung Electronics Co., Ltd.

  公开号：EP3715436A1

  公开（公告）日：2020-09-30

  A composition including a first compound represented by Formula 1 and a second compound represented by Formula 2 and an organic light-emitting device including the composition: Formulae 1 and 2 may each be understood by referring to the descriptions thereof provided herein.

  一种组合物，包括由式 1 表示的第一种化合物和由式 2 表示的第二种化合物，以及一种包括该组合物的有机发光器件： 式 1 和式 2 的含义可参阅本文对其的描述。